Feedback (FDBK) AI Stock Analysis

• Market Cap: £6.46M
• Dividend Yield: N/A
• Average Volume (3M): 26.89K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.03
• Revenue Growth: 34.71%
• EPS Growth: 8.34%
• Country: UK
• Employees: 27
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.14
• Shares Outstanding: 43,814,777
• 10 Day Avg. Volume: 27,226
• 30 Day Avg. Volume: 26,893
• PEG Ratio: 1.21
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: ―

Feedback plc's overall score reflects a mixture of strengths and challenges. Strong balance sheet and strategic corporate alignments are positive, but persistent losses and cash flow issues raise concerns. Technical analysis indicates a bearish trend, while valuation metrics highlight difficulties due to negative earnings.

Feedback Business Overview & Revenue Model

Company Description

Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a patent-protected software tool, which extracts and quantifies texture features in radiological images, assists research into all tumour types, and uncovers biomarkers in medical images; and TexRAD Lung, a software tool for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, a secure clinical communications platform that facilitates the sharing of clinical-grade medical images. Feedback plc was incorporated in 1958 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Feedback (FDBK) makes money through a subscription-based revenue model, offering its software solutions to businesses on a monthly or annual basis. Key revenue streams include software licensing fees, customization services, and premium feature add-ons that provide advanced analytics capabilities. The company also generates income from strategic partnerships with other technology providers, enabling integrations and expanding its service offerings. Additionally, FDBK may earn revenue through consulting services, helping businesses implement and optimize their feedback management strategies.

Feedback Financial Statement Overview

Summary

Feedback demonstrates revenue growth, but persistent losses highlight operational inefficiencies. The balance sheet is strong with no debt, providing a buffer against financial instability. However, cash flow concerns persist, necessitating careful management to sustain operations without external financing.

Income Statement

Revenue growth is observed over the years with a 15.3% increase from 2023 to 2024. However, the company continues to face profitability challenges with negative EBIT and net profit margins, indicating inefficiencies in cost management. The gross profit margin is positive but still low, suggesting limited pricing power or high cost of goods sold.

Balance Sheet

The company has a strong equity position with zero debt, resulting in a favorable debt-to-equity ratio. The equity ratio remains robust, indicating a low reliance on external financing. However, the declining ROE suggests inefficiencies in generating returns from equity investments.

Cash Flow

The company faces cash flow challenges with consistently negative free cash flow, indicating high operational or capital expenditure needs. The operating cash flow to net income ratio is negative, signaling cash flow issues that could impact future operations without external funding.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.19M	1.18M	1.02M	588.58K	287.42K	449.98K
	Gross Profit
603.87K	144.87K	131.39K	-63.68K	213.64K	417.93K
	EBIT
-3.54M	-3.69M	-3.40M	-2.51M	-2.04M	-1.40M
	EBITDA
-2.99M	-2.64M	-2.56M	-1.96M	-2.01M	-1.38M
	Net Income Common Stockholders
-3.24M	-3.30M	-2.92M	-2.12M	-1.62M	-1.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.26M	3.88M	7.32M	10.31M	2.22M	732.65K
	Total Assets
12.20M	8.34M	11.72M	14.30M	5.82M	2.50M
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-7.26M	-3.88M	-7.32M	-10.31M	-2.22M	-732.65K
	Total Liabilities
780.00K	694.18K	855.45K	594.13K	552.83K	728.67K
	Stockholders Equity
11.41M	7.64M	10.87M	13.71M	5.27M	1.77M
Cash Flow		Free Cash Flow
-2.18M	-2.14M	-2.99M	-2.41M	-3.47M	-1.67M
	Operating Cash Flow
-2.17M	-2.13M	-1.74M	-1.25M	-2.03M	-786.04K
	Investing Cash Flow
-1.05M	-1.22M	-1.24M	-1.15M	-1.44M	-883.14K
	Financing Cash Flow
5.11M	0.00	-830.00	10.49M	4.96M	1.86M

Feedback Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FDBK, the sentiment is Neutral. The current price of 14.75 is above the 20-day moving average (MA) of 14.46, below the 50-day MA of 14.79, and below the 200-day MA of 23.81, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 58.71 is Neutral, neither overbought nor oversold. The STOCH value of 77.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:FDBK.

Feedback Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRW	62 Neutral	£728.40M	62.42	4.50%	2.60%	6.74%	54.83%
IXI	60 Neutral	£10.89M	―	-13.85%	―	7.27%	39.64%
INHC	57 Neutral	£9.33M	―	-16.91%	―	8.09%	70.70%
Sector *	54 Neutral	$5.24B	3.26	-44.35%	6.48%	16.78%	-0.10%
FDBK	49 Neutral	£6.46M	―	-31.79%	―	34.71%	8.34%
CNSL		£8.33M	48.57	1.85%	―	―	―
TRLS		£1.29M	―	-49.33%	―	―	―

Feedback Corporate Events

Feedback plc Navigates NHS Changes with Optimism and Strategic Flexibility

Feedback plc has announced a trading update for the year ending 31 May 2025, highlighting challenges due to changes in NHS funding and organizational structures, which have delayed expected contract awards. Despite a projected revenue decline to £0.9m, the company remains financially stable with £6.6m in cash and investments. The shift in NHS funding models offers greater flexibility for Feedback’s contracting with Integrated Care Boards (ICBs), aligning with its G-Cloud pricing model. The company is optimistic about future opportunities, particularly in digitization and the NHS’s Neighbourhood Health model, and recently received recognition for its contributions to clinical redesign.

Spark’s Take on GB:FDBK Stock

According to Spark, TipRanks’ AI Analyst, GB:FDBK is a Neutral.

Feedback plc’s stock score reflects a mixture of strengths and challenges. The financial performance is bolstered by a strong balance sheet, but ongoing losses and cash flow issues remain concerns. Technical analysis indicators suggest a bearish trend, while valuation metrics highlight the difficulties in assessing the stock’s worth due to negative earnings. Corporate events provide a positive outlook, with strategic partnerships and funding supporting potential future growth.

To see Spark’s full report on GB:FDBK stock, click here.

Feedback plc Reports Strong Half-Year Results and Strategic Alignments

Feedback plc has announced its half-year results, highlighting key operational and financial achievements. The company secured a significant contract with Queen Victoria Hospital NHS Foundation Trust and received additional funding to expand its community diagnostic center pilot. Feedback’s Bleepa platform was approved for reimbursement through the Elective Recovery Fund, aligning with the UK government’s focus on NHS reform and elective care. Financially, the company reported a 3% increase in revenue and a 43% rise in sales, alongside a reduced EBITDA loss. Post-period, Feedback operationalized projects in India and continued its strategic alignment with NHS England’s priorities, positioning itself for growth amid evolving market conditions.

Feedback plc to Announce Half-Year Results and Host Investor Presentations

Feedback plc has announced that it will release its results for the half year ended 30 November 2024 on 25 February 2025, accompanied by analyst and investor presentations on the same day. These events are significant for stakeholders as they will provide insights into the company’s performance and future prospects, potentially impacting its market positioning and growth trajectory.